Abstracts tagged "biomarkers and proteomics"

Abstract Number: 1868 • 2019 ACR/ARP Annual Meeting
Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis
Rie Karasawa¹, James N. Jarvis ², Toshiko Sato ¹, Megumi Tanaka ¹, Mark Hicar ², Kazuo Yudoh ¹, Terrance O’Hanlon ³, Payam Noroozi-Farhadi ³ and Lisa G. Rider ⁴, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, ³NIEHS, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory myopathy characterized by prominent vascular and perivascular inflammation in affected skeletal muscles. The mechanisms of vessel injury in…
Abstract Number: 765 • 2017 ACR/ARHP Annual Meeting
Proteomic Analysis of Scleroderma Associated Joint Disease
Chan Kim¹, Julio Mantero², Robert A. Lafyatis³ and Robert W. Simms⁴, ¹Rheumatology and Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Arthritis Center, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: The pathophysiology of joint disease in scleroderma, a heterogeneous multisystem disease mostly characterized by fibrosis, is unknown. We performed proteomic analysis of serum in…
Abstract Number: 1253 • 2015 ACR/ARHP Annual Meeting
Identification and Validation of Novel Putative Salivary Proteomic Biomarkers in Sjögren’s Syndrome and Different Disease Subsets
Chiara Baldini¹, Daniela Martini¹, Nadia Ucciferri², Silvia Rocchiccioli², Letizia Mattii³, Antonietta Raffaella Maria Sabbatini³, Francesca Sernissi¹, Francesco Ferro¹, Nicoletta Luciano¹, Leonardo Lorenzini¹, Marta Mosca⁴, Stefano Bombardieri¹ and Antonella Cecchettini³, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²Institute of Clinical Physiology, Pisa, Italy, Pisa, Italy, ³Department of Clinical and Experimental Medicine, University of Pisa, Italy, Pisa, Italy, ⁴University of Pisa, Pisa, Italy
Background/Purpose: Salivary proteomics has recently appeared as a promising tool for the identification of novel diagnostic biomarkers for primary Sjögren’s syndrome (SS). However, to date…
Abstract Number: 2977 • 2014 ACR/ARHP Annual Meeting
Distinct Serum Protein Signature and Novel Biomarkers of primary Sjogren’s Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis
Ayumi Nishikawa¹, Katsuya Suzuki², Yoshiaki Kassai³, Yuumi Gotou⁴, Takahiro Miyazaki³, Maiko Takiguchi⁵, Masaru Takeshita¹, Atsuko Murota², Rimpei Morita⁶, Akihiko Yoshimura⁶ and Tsutomu Takeuchi², ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, ⁵Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Japan, ⁶Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The EULAR SS Disease Activity Index (ESSDAI) is currently used as an objective evaluation method of clinical disease activity in clinical research into primary…
Abstract Number: 2645 • 2013 ACR/ARHP Annual Meeting
Pathological Roles Of The Anti-Oxidative Enzyme Peroxiredoxin 2 In Patients With Kawasaki Disease
Rie Karasawa¹, Toshiko Sato¹, Mayumi Tamaki¹, Mikiya Fujieda², Kazuhide Ohta³ and Kazuo Yudoh¹, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Pediatrics, Kochi Medical School, Nankoku, Japan, ³Department of Pediatrics, Kanazawa Medical Center, Kanazawa, Japan
Background/Purpose: Anti-endothelial cell antibodies (AECA) are autoantibodies that are detected frequently in vasculitis caused by, for example, Kawasaki disease (KD). However, AECA target molecules have…
Abstract Number: 1905 • 2013 ACR/ARHP Annual Meeting
Protein Profiles Of Peripheral Blood Mononuclear Cells As a Biomarker For Behcet’s Disease
Manae Kurokawa¹, Takuya Yoshioka², Toshiyuki Sato¹, Kouhei Nagai¹, Nobuko Iizuka¹, Mitsumi Arito¹, Yukiko Takakuwa², Hiromasa Nakano², Seido Ooka², Naoya Suematsu¹, Kazuki Okamoto¹, HIroshi Nakamura³, Noboru Suzuki⁴, Shoichi Ozaki⁵ and Tomohiro Kato¹, ¹Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Department of Rheumatology, Nippon Medical School, Bunkyo-ku, Japan, ⁴Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: To investigate the pathophysiology of Behcet’s disease (BD) and find biomarker candidates for the disease, we analyzed protein profiles of peripheral blood mononuclear cells…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].